REFERENCES
Alexander, S.P., Christopoulos, A., Davenport, A.P., Kelly, E., Mathie,
A., Peters, J.A., et al. (2021). THE CONCISE GUIDE TO PHARMACOLOGY
2021/22: G protein-coupled receptors. Br J Pharmacol 178 Suppl 1 :
S27–S156.
Amodeo, D.A., Cuevas, L., Dunn, J.T., Sweeney, J.A., and Ragozzino, M.E.
(2018). The adenosine A2A receptor agonist, CGS 21680, attenuates a
probabilistic reversal learning deficit and elevated grooming behavior
in BTBR mice. Autism Res 11 : 223–233.
Andari, E., Duhamel, J.-R., Zalla, T., Herbrecht, E., Leboyer, M., and
Sirigu, A. (2010). Promoting social behavior with oxytocin in
high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A107 : 4389–4394.
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad,
N., et al. (2021). Cannabinoid treatment for autism: a proof-of-concept
randomized trial. Mol Autism 12 : 6.
Bast, N., Poustka, L., and Freitag, C.M. (2018). The locus
coeruleus-norepinephrine system as pacemaker of attention - a
developmental mechanism of derailed attentional function in autism
spectrum disorder. Eur J Neurosci 47 : 115–125.
Beaulieu, J.-M., and Gainetdinov, R.R. (2011). The physiology,
signaling, and pharmacology of dopamine receptors. Pharmacol Rev63 : 182–217.
Bedogni, F., Cobolli Gigli, C., Pozzi, D., Rossi, R.L., Scaramuzza, L.,
Rossetti, G., et al. (2016). Defects During Mecp2 Null Embryonic Cortex
Development Precede the Onset of Overt Neurological Symptoms. Cereb
Cortex 26 : 2517–2529.
Beerepoot, P., Nazari, R., and Salahpour, A. (2017). Pharmacological
chaperone approaches for rescuing GPCR mutants: Current state,
challenges, and screening strategies. Pharmacol Res 117 :
242–251.
Berendzen, K.M., Sharma, R., Mandujano, M.A., Wei, Y., Rogers, F.D.,
Simmons, T.C., et al. (2022). Oxytocin receptor is not required for
social attachment in prairie voles. Neuron S0896-6273(22)01084–4.
Berger, M., Gray, J.A., and Roth, B.L. (2009). The expanded biology of
serotonin. Annu Rev Med 60 : 355–366.
Berry-Kravis, E.M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini,
M., Walton-Bowen, K., et al. (2012). Effects of STX209 (arbaclofen) on
neurobehavioral function in children and adults with fragile X syndrome:
a randomized, controlled, phase 2 trial. Sci Transl Med 4 :
152ra127.
Bever, Y. van, Rooms, L., Laridon, A., Reyniers, E., Luijk, R. van,
Scheers, S., et al. (2005). Clinical report of a pure subtelomeric 1qter
deletion in a boy with mental retardation and multiple anomalies adds
further evidence for a specific phenotype. Am J Med Genet A 135 :
91–95.
Beversdorf, D.Q. (2020). The Role of the Noradrenergic System in Autism
Spectrum Disorders, Implications for Treatment. Semin Pediatr Neurol35 : 100834.
Blanchard, R.J., Griebel, G., Farrokhi, C., Markham, C., Yang, M., and
Blanchard, D.C. (2005). AVP V1b selective antagonist SSR149415 blocks
aggressive behaviors in hamsters. Pharmacol Biochem Behav 80 :
189–194.
Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks,
M., Murtagh, L., et al. (2019). A phase 2 clinical trial of a
vasopressin V1a receptor antagonist shows improved adaptive behaviors in
men with autism spectrum disorder. Sci Transl Med 11 : eaat7838.
Brody, S.A., Dulawa, S.C., Conquet, F., and Geyer, M.A. (2004).
Assessment of a prepulse inhibition deficit in a mutant mouse lacking
mGlu5 receptors. Mol Psychiatry 9 : 35–41.
Campbell, N.G., Zhu, C.-B., Lindler, K.M., Yaspan, B.L.,
Kistner-Griffin, E., NIH ARRA Consortium, et al. (2013). Rare coding
variants of the adenosine A3 receptor are increased in autism: on the
trail of the serotonin transporter regulome. Mol Autism 4 : 28.
Campi, K.L., Greenberg, G.D., Kapoor, A., Ziegler, T.E., and Trainor,
B.C. (2014). Sex differences in effects of dopamine D1 receptors on
social withdrawal. Neuropharmacology 77 : 208–216.
Carreira, L.D., Matias, F.C., and Campos, M.G. (2022). Clinical Data on
Canabinoids: Translational Research in the Treatment of Autism Spectrum
Disorders. Biomedicines 10 : 796.
Cataldo, I., Azhari, A., and Esposito, G. (2018). A Review of Oxytocin
and Arginine-Vasopressin Receptors and Their Modulation of Autism
Spectrum Disorder. Front Mol Neurosci 11 : 27.
Chadman, K.K., Fernandes, S., DiLiberto, E., and Feingold, R. (2019). Do
animal models hold value in Autism spectrum disorder (ASD) drug
discovery? Expert Opin Drug Discov 14 : 727–734.
Chana, G., Laskaris, L., Pantelis, C., Gillett, P., Testa, R., Zantomio,
D., et al. (2015). Decreased expression of mGluR5 within the
dorsolateral prefrontal cortex in autism and increased microglial number
in mGluR5 knockout mice: Pathophysiological and neurobehavioral
implications. Brain Behav Immun 49 : 197–205.
Chartoff, E.H., Marck, B.T., Matsumoto, A.M., Dorsa, D.M., and Palmiter,
R.D. (2001). Induction of stereotypy in dopamine-deficient mice requires
striatal D1 receptor activation. Proc Natl Acad Sci U S A 98 :
10451–10456.
Chen, Q., Kogan, J.H., Gross, A.K., Zhou, Y., Walton, N.M., Shin, R., et
al. (2012). SREB2/GPR85, a schizophrenia risk factor, negatively
regulates hippocampal adult neurogenesis and neurogenesis-dependent
learning and memory. Eur J Neurosci 36 : 2597–2608.
Ciruela, F., Gómez-Soler, M., Guidolin, D., Borroto-Escuela, D.O.,
Agnati, L.F., Fuxe, K., et al. (2011). Adenosine receptor containing
oligomers: their role in the control of dopamine and glutamate
neurotransmission in the brain. Biochim Biophys Acta 1808 :
1245–1255.
Coelho, J.E., Alves, P., Canas, P.M., Valadas, J.S., Shmidt, T.,
Batalha, V.L., et al. (2014). Overexpression of Adenosine A2A Receptors
in Rats: Effects on Depression, Locomotion, and Anxiety. Front
Psychiatry 5 : 67.
D’Antoni, S., Spatuzza, M., Bonaccorso, C.M., Musumeci, S.A., Ciranna,
L., Nicoletti, F., et al. (2014). Dysregulation of group-I metabotropic
glutamate (mGlu) receptor mediated signalling in disorders associated
with Intellectual Disability and Autism. Neurosci Biobehav Rev 46
Pt 2 : 228–241.
De la Cruz, O., Blekhman, R., Zhang, X., Nicolae, D., Firestein, S., and
Gilad, Y. (2009). A signature of evolutionary constraint on a subset of
ectopically expressed olfactory receptor genes. Mol Biol Evol 26 :
491–494.
De Nuccio, C., Bernardo, A., Ferrante, A., Pepponi, R., Martire, A.,
Falchi, M., et al. (2019). Adenosine A2A receptor stimulation restores
cell functions and differentiation in Niemann-Pick type C-like
oligodendrocytes. Sci Rep 9 : 9782.
De Rubeis, S., He, X., Goldberg, A.P., Poultney, C.S., Samocha, K.,
Cicek, A.E., et al. (2014). Synaptic, transcriptional and chromatin
genes disrupted in autism. Nature 515 : 209–215.
Dekan, Z., Kremsmayr, T., Keov, P., Godin, M., Teakle, N., Dürrauer, L.,
et al. (2021). Nature-inspired dimerization as a strategy to modulate
neuropeptide pharmacology exemplified with vasopressin and oxytocin.
Chem Sci 12 : 4057–4062.
Di Prisco, G.V., Huang, W., Buffington, S.A., Hsu, C.-C., Bonnen, P.E.,
Placzek, A.N., et al. (2014). Translational control of mGluR-dependent
long-term depression and object-place learning by eIF2α. Nat Neurosci17 : 1073–1082.
DiCarlo, G.E., Aguilar, J.I., Matthies, H.J., Harrison, F.E., Bundschuh,
K.E., West, A., et al. (2019). Autism-linked dopamine transporter
mutation alters striatal dopamine neurotransmission and
dopamine-dependent behaviors. J Clin Invest 129 : 3407–3419.
Dumais, K.M., Bredewold, R., Mayer, T.E., and Veenema, A.H. (2013). Sex
differences in oxytocin receptor binding in forebrain regions:
correlations with social interest in brain region- and sex- specific
ways. Horm Behav 64 : 693–701.
Dunham, J.H., Meyer, R.C., Garcia, E.L., and Hall, R.A. (2009). GPR37
surface expression enhancement via N-terminal truncation or
protein-protein interactions. Biochemistry 48 : 10286–10297.
El Khamlichi, C., Reverchon, F., Hervouet-Coste, N., Robin, E., Chopin,
N., Deau, E., et al. (2022). Serodolin, a β-arrestin-biased ligand of
5-HT7 receptor, attenuates pain-related behaviors. Proc Natl Acad Sci U
S A 119 : e2118847119.
Elands, J., Barberis, C., and Jard, S. (1988).
[3H]-[Thr4,Gly7]OT: a highly selective ligand for central and
peripheral OT receptors. Am J Physiol 254 : E31-38.
Farook, M.F., DeCuypere, M., Hyland, K., Takumi, T., LeDoux, M.S., and
Reiter, L.T. (2012). Altered serotonin, dopamine and norepinepherine
levels in 15q duplication and Angelman syndrome mouse models. PLoS One7 : e43030.
Fatemi, S.H., Folsom, T.D., Kneeland, R.E., and Liesch, S.B. (2011).
Metabotropic glutamate receptor 5 upregulation in children with autism
is associated with underexpression of both Fragile X mental retardation
protein and GABAA receptor beta 3 in adults with autism. Anat Rec
(Hoboken) 294 : 1635–1645.
Fatemi, S.H., Folsom, T.D., Reutiman, T.J., and Thuras, P.D. (2009).
Expression of GABA(B) receptors is altered in brains of subjects with
autism. Cerebellum 8 : 64–69.
Ferguson, J.N., Aldag, J.M., Insel, T.R., and Young, L.J. (2001).
Oxytocin in the medial amygdala is essential for social recognition in
the mouse. J Neurosci 21 : 8278–8285.
Firouzabadi, N., Ghazanfari, N., Alavi Shoushtari, A., Erfani, N.,
Fathi, F., Bazrafkan, M., et al. (2016). Genetic Variants of
Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control
Study. PLoS One 11 : e0153667.
Fish, E.W., Faccidomo, S., and Miczek, K.A. (1999). Aggression
heightened by alcohol or social instigation in mice: reduction by the
5-HT(1B) receptor agonist CP-94,253. Psychopharmacology (Berl)146 : 391–399.
Fisher, N.M., AlHashim, A., Buch, A.B., Badivuku, H., Samman, M.M.,
Weiss, K.M., et al. (2021). A GRM7 mutation associated with
developmental delay reduces mGlu7 expression and produces neurological
phenotypes. JCI Insight 6 : e143324, 143324.
Fisher, N.M., Gould, R.W., Gogliotti, R.G., McDonald, A.J., Badivuku,
H., Chennareddy, S., et al. (2020). Phenotypic profiling of mGlu7
knockout mice reveals new implications for neurodevelopmental disorders.
Genes Brain Behav 19 : e12654.
Frantz, M.-C., Pellissier, L.P., Pflimlin, E., Loison, S., Gandía, J.,
Marsol, C., et al. (2018). LIT-001, the First Nonpeptide Oxytocin
Receptor Agonist that Improves Social Interaction in a Mouse Model of
Autism. J Med Chem 61 : 8670–8692.
Froemke, R.C., and Young, L.J. (2021). Oxytocin, Neural Plasticity, and
Social Behavior. Annu Rev Neurosci 44 : 359–381.
Fujita-Jimbo, E., Tanabe, Y., Yu, Z., Kojima, K., Mori, M., Li, H., et
al. (2015). The association of GPR85 with PSD-95-neuroligin complex and
autism spectrum disorder: a molecular analysis. Mol Autism 6 : 17.
Gabriele, S., Sacco, R., and Persico, A.M. (2014). Blood serotonin
levels in autism spectrum disorder: a systematic review and
meta-analysis. Eur Neuropsychopharmacol 24 : 919–929.
Gazestani, V.H., Pramparo, T., Nalabolu, S., Kellman, B.P., Murray, S.,
Lopez, L., et al. (2019). A perturbed gene network containing PI3K-AKT,
RAS-ERK and WNT-β-catenin pathways in leukocytes is linked to ASD
genetics and symptom severity. Nat Neurosci 22 : 1624–1634.
Gidaya, N.B., Lee, B.K., Burstyn, I., Michael, Y., Newschaffer, C.J.,
and Mortensen, E.L. (2016). In utero Exposure to β-2-Adrenergic Receptor
Agonist Drugs and Risk for Autism Spectrum Disorders. Pediatrics137 : e20151316.
Gilbert, D.L., Murphy, T.K., Jankovic, J., Budman, C.L., Black, K.J.,
Kurlan, R.M., et al. (2018). Ecopipam, a D1 receptor antagonist, for
treatment of tourette syndrome in children: A randomized,
placebo-controlled crossover study. Mov Disord 33 : 1272–1280.
Gogliotti, R.G., Senter, R.K., Fisher, N.M., Adams, J., Zamorano, R.,
Walker, A.G., et al. (2017). mGlu7 potentiation rescues cognitive,
social, and respiratory phenotypes in a mouse model of Rett syndrome.
Sci Transl Med 9 : eaai7459.
Gomez-Castro, F., Zappettini, S., Pressey, J.C., Silva, C.G., Russeau,
M., Gervasi, N., et al. (2021). Convergence of adenosine and GABA
signaling for synapse stabilization during development. Science374 : eabk2055.
Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J.,
Lambert, T.J., et al. (2010a). Intranasal oxytocin improves emotion
recognition for youth with autism spectrum disorders. Biol Psychiatry67 : 692–694.
Guastella, A.J., Kenyon, A.R., Alvares, G.A., Carson, D.S., and Hickie,
I.B. (2010b). Intranasal arginine vasopressin enhances the encoding of
happy and angry faces in humans. Biol Psychiatry 67 : 1220–1222.
Guerrero, A. (2018). A2A Adenosine Receptor Agonists and their Potential
Therapeutic Applications. An Update. Curr Med Chem 25 :
3597–3612.
Hammock, E. a. D., Lim, M.M., Nair, H.P., and Young, L.J. (2005).
Association of vasopressin 1a receptor levels with a regulatory
microsatellite and behavior. Genes Brain Behav 4 : 289–301.
Hauser, A.S., Attwood, M.M., Rask-Andersen, M., Schiöth, H.B., and
Gloriam, D.E. (2017). Trends in GPCR drug discovery: new agents, targets
and indications. Nat Rev Drug Discov 16 : 829–842.
Hauser, A.S., Chavali, S., Masuho, I., Jahn, L.J., Martemyanov, K.A.,
Gloriam, D.E., et al. (2018). Pharmacogenomics of GPCR Drug Targets.
Cell 172 : 41-54.e19.
Hegarty, J.P., Ferguson, B.J., Zamzow, R.M., Rohowetz, L.J., Johnson,
J.D., Christ, S.E., et al. (2017). Beta-adrenergic antagonism modulates
functional connectivity in the default mode network of individuals with
and without autism spectrum disorder. Brain Imaging Behav 11 :
1278–1289.
Henderson, C., Wijetunge, L., Kinoshita, M.N., Shumway, M., Hammond,
R.S., Postma, F.R., et al. (2012). Reversal of disease-related
pathologies in the fragile X mouse model by selective activation of
GABAB receptors with arbaclofen. Sci Transl Med 4 : 152ra128.
Hertz, E., Terenius, L., Vukojević, V., and Svenningsson, P. (2019).
GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live
cells. Neuropharmacology 152 : 51–57.
Hiraki, Y., Okamoto, N., Ida, T., Nakata, Y., Kamada, M., Kanemura, Y.,
et al. (2008). Two new cases of pure 1q terminal deletion presenting
with brain malformations. Am J Med Genet A 146A : 1241–1247.
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C.M.,
Aronowitz, B.R., et al. (2003). Oxytocin infusion reduces repetitive
behaviors in adults with autistic and Asperger’s disorders.
Neuropsychopharmacology 28 : 193–198.
Hopkins, W.D., Donaldson, Z.R., and Young, L.J. (2012). A polymorphic
indel containing the RS3 microsatellite in the 5’ flanking region of the
vasopressin V1a receptor gene is associated with chimpanzee (Pan
troglodytes) personality. Genes Brain Behav 11 : 552–558.
Horie, K., Inoue, K., Suzuki, S., Adachi, S., Yada, S., Hirayama, T., et
al. (2019). Oxytocin receptor knockout prairie voles generated by
CRISPR/Cas9 editing show reduced preference for social novelty and
exaggerated repetitive behaviors. Horm Behav 111 : 60–69.
Hormozdiari, F., Penn, O., Borenstein, E., and Eichler, E.E. (2015). The
discovery of integrated gene networks for autism and related disorders.
Genome Res 25 : 142–154.
Imai, Y., Inoue, H., Kataoka, A., Hua-Qin, W., Masuda, M., Ikeda, T., et
al. (2007). Pael receptor is involved in dopamine metabolism in the
nigrostriatal system. Neurosci Res 59 : 413–425.
Jacob, S., Veenstra-VanderWeele, J., Murphy, D., McCracken, J., Smith,
J., Sanders, K., et al. (2022). Efficacy and safety of balovaptan for
socialisation and communication difficulties in autistic adults in North
America and Europe: a phase 3, randomised, placebo-controlled trial.
Lancet Psychiatry 9 : 199–210.
Jacquemont, S., Berry-Kravis, E., Hagerman, R., Raison, F. von,
Gasparini, F., Apostol, G., et al. (2014). The challenges of clinical
trials in fragile X syndrome. Psychopharmacology (Berl) 231 :
1237–1250.
Jacquemont, S., Curie, A., Portes, V. des, Torrioli, M.G., Berry-Kravis,
E., Hagerman, R.J., et al. (2011). Epigenetic modification of the FMR1
gene in fragile X syndrome is associated with differential response to
the mGluR5 antagonist AFQ056. Sci Transl Med 3 : 64ra1.
Jin, C., Kang, H., Ryu, J.R., Kim, S., Zhang, Y., Lee, Y., et al.
(2018). Integrative Brain Transcriptome Analysis Reveals Region-Specific
and Broad Molecular Changes in Shank3-Overexpressing Mice. Front Mol
Neurosci 11 : 250.
Jing, F., Mogi, M., Sakata, A., Iwanami, J., Tsukuda, K., Ohshima, K.,
et al. (2012). Direct stimulation of angiotensin II type 2 receptor
enhances spatial memory. J Cereb Blood Flow Metab 32 : 248–255.
John, S., and Jaeggi, A.V. (2021). Oxytocin levels tend to be lower in
autistic children: A meta-analysis of 31 studies. Autism 25 :
2152–2161.
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M.J., Kreutzberg, G.W.,
Sher, A., et al. (2000). Analysis of fractalkine receptor CX(3)CR1
function by targeted deletion and green fluorescent protein reporter
gene insertion. Mol Cell Biol 20 : 4106–4114.
Jurek, B., and Neumann, I.D. (2018). The Oxytocin Receptor: From
Intracellular Signaling to Behavior. Physiol Rev 98 : 1805–1908.
Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., et al.
(2011). Spatio-temporal transcriptome of the human brain. Nature478 : 483–489.
Khan, M.Z., and He, L. (2017). Neuro-psychopharmacological perspective
of Orphan receptors of Rhodopsin (class A) family of G protein-coupled
receptors. Psychopharmacology (Berl) 234 : 1181–1207.
Koshimizu, T., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H.,
and Tanoue, A. (2012). Vasopressin V1a and V1b receptors: from molecules
to physiological systems. Physiol Rev 92 : 1813–1864.
Laboute, T., Gandía, J., Pellissier, L.P., Corde, Y., Rebeillard, F.,
Gallo, M., et al. (2020). The orphan receptor GPR88 blunts the signaling
of opioid receptors and multiple striatal GPCRs. Elife 9 : e50519.
Lacivita, E., Niso, M., Mastromarino, M., Garcia Silva, A., Resch, C.,
Zeug, A., et al. (2021). Knowledge-Based Design of Long-Chain
Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as
Potential Candidates for Treatment of Autism Spectrum Disorder. ACS Chem
Neurosci 12 : 1313–1327.
Lee, Y., Kim, H., Kim, J.-E., Park, J.-Y., Choi, J., Lee, J.-E., et al.
(2018). Excessive D1 Dopamine Receptor Activation in the Dorsal Striatum
Promotes Autistic-Like Behaviors. Mol Neurobiol 55 : 5658–5671.
León, K., Boulo, T., Musnier, A., Morales, J., Gauthier, C., Dupuy, L.,
et al. (2014). Activation of a GPCR leads to eIF4G phosphorylation at
the 5’ cap and to IRES-dependent translation. J Mol Endocrinol52 : 373–382.
Leppanen, J., Ng, K.W., Kim, Y.-R., Tchanturia, K., and Treasure, J.
(2018). Meta-analytic review of the effects of a single dose of
intranasal oxytocin on threat processing in humans. J Affect Disord225 : 167–179.
Lewis, M.H., Rajpal, H., and Muehlmann, A.M. (2019). Reduction of
repetitive behavior by co-administration of adenosine receptor agonists
in C58 mice. Pharmacol Biochem Behav 181 : 110–116.
Li, W., and Pozzo-Miller, L. (2020). Dysfunction of the corticostriatal
pathway in autism spectrum disorders. J Neurosci Res 98 :
2130–2147.
Li, X., Gardner, E.L., and Xi, Z.-X. (2008). The metabotropic glutamate
receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus
accumbens GABA and glutamate, but not dopamine, in rats.
Neuropharmacology 54 : 542–551.
Lohith, T.G., Osterweil, E.K., Fujita, M., Jenko, K.J., Bear, M.F., and
Innis, R.B. (2013). Is metabotropic glutamate receptor 5 upregulated in
prefrontal cortex in fragile X syndrome? Mol Autism 4 : 15.
Lozano, R., Martinez-Cerdeno, V., and Hagerman, R.J. (2015). Advances in
the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles
Leading to Targeted Treatments for Fragile X Spectrum Disorder. Curr
Pharm Des 21 : 4972–4979.
Lukens, J.R., and Eyo, U.B. (2022). Microglia and Neurodevelopmental
Disorders. Annu Rev Neurosci 45 : 425–445.
Lüscher, C., Jan, L.Y., Stoffel, M., Malenka, R.C., and Nicoll, R.A.
(1997). G protein-coupled inwardly rectifying K+ channels (GIRKs)
mediate postsynaptic but not presynaptic transmitter actions in
hippocampal neurons. Neuron 19 : 687–695.
Macdonald, K., and Macdonald, T.M. (2010). The peptide that binds: a
systematic review of oxytocin and its prosocial effects in humans. Harv
Rev Psychiatry 18 : 1–21.
Madsen, D., Azevedo, C., Micco, I., Petersen, L.K., and Hansen, N.J.V.
(2020). An overview of DNA-encoded libraries: A versatile tool for drug
discovery. Prog Med Chem 59 : 181–249.
Maguire, G.A., Riley, G.D., Franklin, D.L., Maguire, M.E., Nguyen, C.T.,
and Brojeni, P.H. (2004). Olanzapine in the treatment of developmental
stuttering: a double-blind, placebo-controlled trial. Ann Clin
Psychiatry 16 : 63–67.
Mahdavinasab, S.-M., Saghazadeh, A., Motamed-Gorji, N., Vaseghi, S.,
Mohammadi, M.-R., Alichani, R., et al. (2019). Baclofen as an adjuvant
therapy for autism: a randomized, double-blind, placebo-controlled
trial. Eur Child Adolesc Psychiatry 28 : 1619–1628.
Manahan-Vaughan, D., and Reymann, K.G. (1995). Regional and
developmental profile of modulation of hippocampal synaptic transmission
and LTP by AP4-sensitive mGluRs in vivo. Neuropharmacology 34 :
991–1001.
Manoli, D.S., and State, M.W. (2021). Autism Spectrum Disorder Genetics
and the Search for Pathological Mechanisms. Am J Psychiatry 178 :
30–38.
Mantella, R.C., Vollmer, R.R., Li, X., and Amico, J.A. (2003). Female
oxytocin-deficient mice display enhanced anxiety-related behavior.
Endocrinology 144 : 2291–2296.
Marazziti, D., Mandillo, S., Di Pietro, C., Golini, E., Matteoni, R.,
and Tocchini-Valentini, G.P. (2007). GPR37 associates with the dopamine
transporter to modulate dopamine uptake and behavioral responses to
dopaminergic drugs. Proc Natl Acad Sci U S A 104 : 9846–9851.
Marti-Solano, M., Crilly, S.E., Malinverni, D., Munk, C., Harris, M.,
Pearce, A., et al. (2020). Combinatorial expression of GPCR isoforms
affects signalling and drug responses. Nature 587 : 650–656.
Matsumoto, M., Straub, R.E., Marenco, S., Nicodemus, K.K., Matsumoto,
S.-I., Fujikawa, A., et al. (2008). The evolutionarily conserved G
protein-coupled receptor SREB2/GPR85 influences brain size, behavior,
and vulnerability to schizophrenia. Proc Natl Acad Sci U S A 105 :
6133–6138.
McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E.,
Davies, M., et al. (2005). Risperidone for the core symptom domains of
autism: results from the study by the autism network of the research
units on pediatric psychopharmacology. Am J Psychiatry 162 :
1142–1148.
Meyer-Lindenberg, A., Kolachana, B., Gold, B., Olsh, A., Nicodemus,
K.K., Mattay, V., et al. (2009). Genetic variants in AVPR1A linked to
autism predict amygdala activation and personality traits in healthy
humans. Mol Psychiatry 14 : 968–975.
Ming, X., Gordon, E., Kang, N., and Wagner, G.C. (2008). Use of
clonidine in children with autism spectrum disorders. Brain Dev30 : 454–460.
Mishra, A., Singh, S., and Shukla, S. (2018). Physiological and
Functional Basis of Dopamine Receptors and Their Role in Neurogenesis:
Possible Implication for Parkinson’s disease. J Exp Neurosci 12 :
1179069518779829.
Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic,
S., et al. (2005). A selective metabotropic glutamate receptor 7
agonist: activation of receptor signaling via an allosteric site
modulates stress parameters in vivo. Proc Natl Acad Sci U S A102 : 18712–18717.
Monfared, R.V., Alhassen, W., Truong, T.M., Gonzales, M.A.M.,
Vachirakorntong, V., Chen, S., et al. (2021). Transcriptome Profiling of
Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric
Disorders and Age-Disease Interactions. Cells 10 : 2967.
Mujić-Delić, A., Wit, R.H. de, Verkaar, F., and Smit, M.J. (2014).
GPCR-targeting nanobodies: attractive research tools, diagnostics, and
therapeutics. Trends Pharmacol Sci 35 : 247–255.
Muller, C.L., Anacker, A.M.J., and Veenstra-VanderWeele, J. (2016). The
serotonin system in autism spectrum disorder: From biomarker to animal
models. Neuroscience 321 : 24–41.
Musnier, A., León, K., Morales, J., Reiter, E., Boulo, T., Costache, V.,
et al. (2012). mRNA-selective translation induced by FSH in primary
Sertoli cells. Mol Endocrinol 26 : 669–680.
Nakai, N., Nagano, M., Saitow, F., Watanabe, Y., Kawamura, Y., Kawamoto,
A., et al. (2017). Serotonin rebalances cortical tuning and behavior
linked to autism symptoms in 15q11-13 CNV mice. Sci Adv 3 :
e1603001.
Negyessy, L., and Goldman-Rakic, P.S. (2005). Subcellular localization
of the dopamine D2 receptor and coexistence with the calcium-binding
protein neuronal calcium sensor-1 in the primate prefrontal cortex. J
Comp Neurol 488 : 464–475.
Nelson, S.B., and Valakh, V. (2015). Excitatory/Inhibitory Balance and
Circuit Homeostasis in Autism Spectrum Disorders. Neuron 87 :
684–698.
Nephew, B.C., and Bridges, R.S. (2008). Arginine vasopressin V1a
receptor antagonist impairs maternal memory in rats. Physiol Behav95 : 182–186.
Nisar, S., Bhat, A.A., Masoodi, T., Hashem, S., Akhtar, S., Ali, T.A.,
et al. (2022). Genetics of glutamate and its receptors in autism
spectrum disorder. Mol Psychiatry 27 : 2380–2392.
Oblak, A.L., Gibbs, T.T., and Blatt, G.J. (2010). Decreased GABA(B)
receptors in the cingulate cortex and fusiform gyrus in autism. J
Neurochem 114 : 1414–1423.
Olender, T., Jones, T.E.M., Bruford, E., and Lancet, D. (2020). A
unified nomenclature for vertebrate olfactory receptors. BMC Evol Biol20 : 42.
Olender, T., Keydar, I., Pinto, J.M., Tatarskyy, P., Alkelai, A., Chien,
M.-S., et al. (2016). The human olfactory transcriptome. BMC Genomics17 : 619.
O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe,
B.P., et al. (2012). Sporadic autism exomes reveal a highly
interconnected protein network of de novo mutations. Nature 485 :
246–250.
Parker, K.J., Oztan, O., Libove, R.A., Mohsin, N., Karhson, D.S.,
Sumiyoshi, R.D., et al. (2019). A randomized placebo-controlled pilot
trial shows that intranasal vasopressin improves social deficits in
children with autism. Sci Transl Med 11 : eaau7356.
Passoni, I., Leonzino, M., Gigliucci, V., Chini, B., and Busnelli, M.
(2016). Carbetocin is a Functional Selective Gq Agonist That Does Not
Promote Oxytocin Receptor Recycling After Inducing
β-Arrestin-Independent Internalisation. J Neuroendocrinol 28 :
n/a.
Pellissier, L.P., Pujol, C.N., Becker, J. a. J., and Le Merrer, J.
(2018). Delta Opioid Receptors: Learning and Motivation. Handb Exp
Pharmacol 247 : 227–260.
Perry, E.K., Lee, M.L., Martin-Ruiz, C.M., Court, J.A., Volsen, S.G.,
Merrit, J., et al. (2001). Cholinergic activity in autism: abnormalities
in the cerebral cortex and basal forebrain. Am J Psychiatry 158 :
1058–1066.
Pintacuda, G., Hsu, Y.-H.H., Tsafou, K., Li, K.W., Martín, J.M.,
Riseman, J., et al. (2023). Protein interaction studies in human induced
neurons indicate convergent biology underlying autism spectrum
disorders. Cell Genomics 100250.
Poulin, B., Butcher, A., McWilliams, P., Bourgognon, J.-M., Pawlak, R.,
Kong, K.C., et al. (2010). The M3-muscarinic receptor regulates learning
and memory in a receptor phosphorylation/arrestin-dependent manner. Proc
Natl Acad Sci U S A 107 : 9440–9445.
Pourhamzeh, M., Moravej, F.G., Arabi, M., Shahriari, E., Mehrabi, S.,
Ward, R., et al. (2022). The Roles of Serotonin in Neuropsychiatric
Disorders. Cell Mol Neurobiol 42 : 1671–1692.
Pringsheim, T., and Marras, C. (2009). Pimozide for tics in Tourette’s
syndrome. Cochrane Database Syst Rev 2009 : CD006996.
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., and Devi, L.A.
(2022). Oxytocin and vasopressin: Signalling, behavioural modulation and
potential therapeutic effects. Br J Pharmacol 179 : 1544–1564.
Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical
profiling of G protein-coupled receptor expression. Cell 135 :
561–571.
Román, V., Adham, N., Foley, A.G., Hanratty, L., Farkas, B., Lendvai,
B., et al. (2021). Cariprazine alleviates core behavioral deficits in
the prenatal valproic acid exposure model of autism spectrum disorder.
Psychopharmacology (Berl) 238 : 2381–2392.
Ruhrmann, S., Kissling, W., Lesch, O.-M., Schmauss, M., Seemann, U., and
Philipp, M. (2007). Efficacy of flupentixol and risperidone in chronic
schizophrenia with predominantly negative symptoms. Prog
Neuropsychopharmacol Biol Psychiatry 31 : 1012–1022.
Ruzzo, E.K., Pérez-Cano, L., Jung, J.-Y., Wang, L.-K., Kashef-Haghighi,
D., Hartl, C., et al. (2019). Inherited and De Novo Genetic Risk for
Autism Impacts Shared Networks. Cell 178 : 850-866.e26.
Sala, M., Braida, D., Lentini, D., Busnelli, M., Bulgheroni, E.,
Capurro, V., et al. (2011). Pharmacologic rescue of impaired cognitive
flexibility, social deficits, increased aggression, and seizure
susceptibility in oxytocin receptor null mice: a neurobehavioral model
of autism. Biol Psychiatry 69 : 875–882.
Salomé, N., Stemmelin, J., Cohen, C., and Griebel, G. (2006).
Differential roles of amygdaloid nuclei in the anxiolytic- and
antidepressant-like effects of the V1b receptor antagonist, SSR149415,
in rats. Psychopharmacology (Berl) 187 : 237–244.
Satterstrom, F.K., Kosmicki, J.A., Wang, J., Breen, M.S., De Rubeis, S.,
An, J.-Y., et al. (2020). Large-Scale Exome Sequencing Study Implicates
Both Developmental and Functional Changes in the Neurobiology of Autism.
Cell 180 : 568-584.e23.
Scerbina, T., Chatterjee, D., and Gerlai, R. (2012). Dopamine receptor
antagonism disrupts social preference in zebrafish: a strain comparison
study. Amino Acids 43 : 2059–2072.
Scharf, S.H., Jaeschke, G., Wettstein, J.G., and Lindemann, L. (2015).
Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
Curr Opin Pharmacol 20 : 124–134.
Schlicker, E., Werner, U., Hamon, M., Gozlan, H., Nickel, B., Szelenyi,
I., et al. (1992). Anpirtoline, a novel, highly potent 5-HT1B receptor
agonist with antinociceptive/antidepressant-like actions in rodents. Br
J Pharmacol 105 : 732–738.
Schnider, P., Bissantz, C., Bruns, A., Dolente, C., Goetschi, E.,
Jakob-Roetne, R., et al. (2020). Discovery of Balovaptan, a Vasopressin
1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J
Med Chem 63 : 1511–1525.
Sikich, L., Kolevzon, A., King, B.H., McDougle, C.J., Sanders, K.B.,
Kim, S.-J., et al. (2021). Intranasal Oxytocin in Children and
Adolescents with Autism Spectrum Disorder. N Engl J Med 385 :
1462–1473.
Silverman, J.L., Pride, M.C., Hayes, J.E., Puhger, K.R., Butler-Struben,
H.M., Baker, S., et al. (2015). GABAB Receptor Agonist R-Baclofen
Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse
Models of Autism. Neuropsychopharmacology 40 : 2228–2239.
Song, J.-M., Kang, M., Park, D.-H., Park, S., Lee, S., and Suh, Y.H.
(2021). Pathogenic GRM7 Mutations Associated with Neurodevelopmental
Disorders Impair Axon Outgrowth and Presynaptic Terminal Development. J
Neurosci 41 : 2344–2359.
Soriano, S.G., Amaravadi, L.S., Wang, Y.F., Zhou, H., Yu, G.X., Tonra,
J.R., et al. (2002). Mice deficient in fractalkine are less susceptible
to cerebral ischemia-reperfusion injury. J Neuroimmunol 125 :
59–65.
Soumier, A., Habart, M., Lio, G., Demily, C., and Sirigu, A. (2022).
Differential fate between oxytocin and vasopressin cells in the
developing mouse brain. IScience 25 : 103655.
Surget, A., and Belzung, C. (2008). Involvement of vasopressin in
affective disorders. Eur J Pharmacol 583 : 340–349.
Szczepanska-Sadowska, E., Wsol, A., Cudnoch-Jedrzejewska, A., Czarzasta,
K., and Żera, T. (2022). Multiple Aspects of Inappropriate Action of
Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric
and Neurodegenerative Diseases. J Clin Med 11 : 908.
Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M.A.,
Taulan, M., et al. (2003). Oxytocin and vasopressin V1a and V2 receptors
form constitutive homo- and heterodimers during biosynthesis. Mol
Endocrinol 17 : 677–691.
Tréfier, A., Pellissier, L.P., Musnier, A., Reiter, E., Guillou, F., and
Crépieux, P. (2018). G Protein-Coupled Receptors As Regulators of
Localized Translation: The Forgotten Pathway? Front Endocrinol
(Lausanne) 9 : 17.
Umbricht, D., Del Valle Rubido, M., Hollander, E., McCracken, J.T.,
Shic, F., Scahill, L., et al. (2017). A Single Dose, Randomized,
Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor
Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum
Disorder. Neuropsychopharmacology 42 : 1914–1923.
Varni, J.W., Handen, B.L., Corey-Lisle, P.K., Guo, Z., Manos, G.,
Ammerman, D.K., et al. (2012). Effect of aripiprazole 2 to 15 mg/d on
health-related quality of life in the treatment of irritability
associated with autistic disorder in children: a post hoc analysis of
two controlled trials. Clin Ther 34 : 980–992.
Vassilatis, D.K., Hohmann, J.G., Zeng, H., Li, F., Ranchalis, J.E.,
Mortrud, M.T., et al. (2003). The G protein-coupled receptor repertoires
of human and mouse. Proc Natl Acad Sci U S A 100 : 4903–4908.
Veenstra-VanderWeele, J., Cook, E.H., King, B.H., Zarevics, P.,
Cherubini, M., Walton-Bowen, K., et al. (2017). Arbaclofen in Children
and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled,
Phase 2 Trial. Neuropsychopharmacology 42 : 1390–1398.
Vilardaga, J.-P., Clark, L.J., White, A.D., Sutkeviciute, I., Lee, J.Y.,
and Bahar, I. (2022). Molecular Mechanisms of PTH/PTHrP class B GPCR
Signaling and Pharmacological Implications. Endocr Rev bnac032.
Voineagu, I., Wang, X., Johnston, P., Lowe, J.K., Tian, Y., Horvath, S.,
et al. (2011). Transcriptomic analysis of autistic brain reveals
convergent molecular pathology. Nature 474 : 380–384.
Walsh, J.J., Llorach, P., Cardozo Pinto, D.F., Wenderski, W.,
Christoffel, D.J., Salgado, J.S., et al. (2021). Systemic enhancement of
serotonin signaling reverses social deficits in multiple mouse models
for ASD. Neuropsychopharmacology 46 : 2000–2010.
Walum, H., Westberg, L., Henningsson, S., Neiderhiser, J.M., Reiss, D.,
Igl, W., et al. (2008). Genetic variation in the vasopressin receptor 1a
gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl
Acad Sci U S A 105 : 14153–14156.
Wei, C.J., Li, W., and Chen, J.-F. (2011). Normal and abnormal functions
of adenosine receptors in the central nervous system revealed by genetic
knockout studies. Biochim Biophys Acta 1808 : 1358–1379.
Wei, D., Allsop, S., Tye, K., and Piomelli, D. (2017). Endocannabinoid
Signaling in the Control of Social Behavior. Trends Neurosci 40 :
385–396.
Witt, K.G., Hetrick, S.E., Rajaram, G., Hazell, P., Taylor Salisbury,
T.L., Townsend, E., et al. (2021). Pharmacological interventions for
self-harm in adults. Cochrane Database Syst Rev 1 : CD013669.
Witte, A.M., Moor, M.H.M. de, Majdandžić, M., Verhees, M.W.F.T.,
IJzendoorn, M.H. van, and Bakermans-Kranenburg, M.J. (2022). Effects of
oxytocin and vasopressin administration on human fathers’ sensitive and
challenging parenting: A randomized within-subject controlled trial.
Horm Behav 142 : 105175.
Xu, J., Marshall, J.J., Kraniotis, S., Nomura, T., Zhu, Y., and
Contractor, A. (2021). Genetic disruption of Grm5 causes complex
alterations in motor activity, anxiety and social behaviors. Behav Brain
Res 411 : 113378.
Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T.,
Makita, R., et al. (2001). Mice lacking the M3 muscarinic acetylcholine
receptor are hypophagic and lean. Nature 410 : 207–212.
Yang, H.-J., Vainshtein, A., Maik-Rachline, G., and Peles, E. (2016). G
protein-coupled receptor 37 is a negative regulator of oligodendrocyte
differentiation and myelination. Nat Commun 7 : 10884.
Yoo, Y., Jung, J., Lee, Y.-N., Lee, Y., Cho, H., Na, E., et al. (2017).
GABBR2 mutations determine phenotype in rett syndrome and epileptic
encephalopathy. Ann Neurol 82 : 466–478.
Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M.S., Saxena,
S., et al. (2022). Global prevalence of autism: A systematic review
update. Autism Res 15 : 778–790.
Zelena, D. (2017). Comparison of natural and artificial vasopressin
deficiency: Why is the latter lethal? Russ J Genet Appl Res 7 :
243–248.
Zhan, Y., Paolicelli, R.C., Sforazzini, F., Weinhard, L., Bolasco, G.,
Pagani, F., et al. (2014). Deficient neuron-microglia signaling results
in impaired functional brain connectivity and social behavior. Nat
Neurosci 17 : 400–406.
Zhang, P.-W., Ishiguro, H., Ohtsuki, T., Hess, J., Carillo, F., Walther,
D., et al. (2004). Human cannabinoid receptor 1: 5’ exons, candidate
regulatory regions, polymorphisms, haplotypes and association with
polysubstance abuse. Mol Psychiatry 9 : 916–931.
Zhou, H., Wang, J., Zhang, Y., Shao, F., and Wang, W. (2020). The Role
of Microglial CX3CR1 in Schizophrenia-Related Behaviors Induced by
Social Isolation. Front Integr Neurosci 14 : 551676.